Using PSMA-1007 Imaging for Staging Prostate Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of [18F] PSMA-1007 imaging in the primary staging of prostate cancer in real-world clinical settings. It will collect data on the diagnostic accuracy of this imaging technique compared to traditional methods, focusing on its ability to detect pelvic lymph node involvement. The study will involve a diverse patient population and will address limitations found in previous studies by allowing for long-term observation and a larger sample size. The goal is to generate evidence-based insights that can enhance the management of prostate cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \> 18 years
* Planned \[18F\]PSMA-1007 PET/CT examination in patients with a first diagnosis of prostate cancer
* Informed consent

Exclusion Criteria:

\- Examinations with limited assessability due to technical errors, such as imaging artifacts.

Where it's running

• Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf
  Düsseldorf, North Rhine-Westphalia, Germany Recruiting

Study contacts

• Study coordinator: Emil Novruzov, Medical Doctor
• Email: Emil.Novruzov@med.uni-duesseldorf.de
• Phone: (+49)211 8118540

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Predicting prostate cancer response to neoadjuvant darolutamide with a gene biomarker

  This study tests whether a gene-based PCAI ImmunoScore can predict which high-risk localized or locally advanced prostate cancer patients will have minimal residual disease after 90–120 days of darolutamide before surgery.

  Recruiting at 2 sites Phase 2 Region Stockholm · Gothenburg and 1 other locations · NCT07617272

• Personal preferences for avoiding gynecomastia (Stage 1)

  This project will ask men with prostate cancer and high-risk biochemical recurrence what trade-offs they'd make to avoid breast-related side effects like gynecomastia.

  Recruiting St Vincent's Hospital, Sydney · Sydney, New South Wales · NCT07552922

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.